Neoadjuvant chemoradiotherapy for locally advanced rectal cancer: The debate continues

Francesca De Felice, Daniela Musio, Luciano Izzo, Vincenzo Tombolini

Abstract
Rectal carcinoma represents the 30% of all colorectal cancers, with about 40000 new cases/years. In the past two decades, the management of rectal cancer has made important progress, highlighting the main role of a multimodality strategy approach, combining surgery, radiation therapy and chemotherapy. Nowadays, surgery remains the primary treatment and neoadjuvant chemoradiotherapy, based on fluoropyrimidine (5-FU) continuous infusion, is considered the standard in locally advanced rectal carcinoma. The aim is to reduce the incidence of local recurrence and to perform a conservative surgery. To improve these purposes different drugs combination have been tested in the neoadjuvant setting. At American Society of Clinical Oncology 2014 an important abstract was presented focusing on the role of adding oxaliplatin to the neoadjuvant treatment has been shown to improve disease-free survival from 71.2% to 75.9% (P = 0.03). This editorial was planned to clarify the optimal treatment in patients with locally advanced rectal cancer, considering the results from CAO/ARO/AIO-04 study.

Key words: Chemoradiotherapy; Rectal cancer; Locally advanced disease; Neoadjuvant; Debate

Core tip: This editorial was planned to clarify the optimal treatment in patients with locally advanced rectal cancer, considering the results from CAO/ARO/AIO-04 trial.
patients who received OXP and 5-FU as adjuvant treatment. Considering these results, several groups, despite the absence of a randomised comparison in neoadjuvant setting for rectal cancer, designed phase III studies to test the standard 5-FU-based neoadjuvant treatment vs analogous but new schedule where the monochemotherapy was replaced by a combination of 5-FU and OXP. This drugs-radiation combination have failed in increase primary tumor response in STAR-01 study, ACCORD 12/0405-Prodige-2 study and NSABP-R04 study, whereas the results of the CAO/ARO/AIO-04 study are intriguing. The second arm in the CAO/ARO/AIO-04 study represented a “experimental” schedule, which used a continuous venous infusion of 5-FU 200 mg/m² and a 2-h OXP infusion 50 mg/m². The 5-FU was delivered during days 1-14 and 22-35, whereas the OXP was delivered days 1, 8, 22 and 29. The primary end-point was disease-free survival (DFS) at 3 years, with acute toxicity, compliance and histopathological response as secondary endpoints. A total of 1265 patients were randomly enrolled, 637 were assigned to control arm and 628 to experimental arm. Acute treatment-related toxicity was similar in the two arms except for 7% grade 3-4 sensory neuropathy events in the OXP-5-FU arm - an obvious expected result of the pharmacokinetics of OXP adsorption. The compliance, defined as full prescribed dose of chemotherapy and full dose of radiotherapy was comparable. Pathological complete response (pCR) was gained in 17% of patients on OXP-5-FU vs 13% on 5-FU (P value = 0.038). With a median follow-up of 50 mo, the 3-years DFS rate was 75.9% in the OXP-5-FU arm vs 71.2% in the control (P = 0.03).

What deductions can we reach from this study? A key observation is that compliance to “experimental” schedule is high and successful disease control is achieved. The other published randomised trials - it is important to note that different OXP and fluorourimidine schedules were used in STAR-01 study, ACCORD 12/0405-Prodige-2 study and NSABP-R04 study - used a continuous infusion of chemotherapy during radiation therapy. Therefore, the one week gap from the conventional administration of 5-FU and OXP is a valid option, with a more tolerable profile. Achieve pCR is a good end-point in rectal cancer, and could be used as prognostic factor - pCR is correlated to excellent long-term prognosis - to recommend a “wait and see” approach, without adjuvant chemotherapy.

So where do we go from here? There is a considerable agreement in the administration of adjuvant chemotherapy plus radiotherapy for the treatment of locally advanced rectal cancer. In many of the trials undertaken and those that are ongoing, 5-FU-based chemoradiotherapy represents the cornerstone, due to fluoropyrimidine well-established potentiating effect with radiation. OXP should be added to influence the tumour cell sensitivity, resulting in a higher rate of down-staging, delineating different subgroups of patients and changing the risk of recurrences. Although the addition of oxaliplatin to standard neoadjuvant regimen appears tolerable, it is true that the real benefit of OXP-5-FU remains unclear. The CAO/ARO/AIO-04 study has confirmed a DFS improvement; do we therefore conclude that OXP-5-FU combination provides indication of survival benefit in locally advanced rectal cancer? There are not randomized studies that have shown a statistical benefit from adding OXP to standard chemoradiotherapy. Certainly, the results of the CAO/ARO/AIO-04 study represent a step in the right direction: it demonstrates the feasibility of neoadjuvant-intensified chemoradiotherapy in a multidisciplinary treatment approach setting for rectal cancer.

ACKNOWLEDGMENTS

The study was performed in PhD program “Tecnologica Avanzate in Chirurgia, curriculum chirurgia”, “Sapienza” University of Rome.

REFERENCES

1. Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V. Neoadjuvant-intensified treatment for rectal cancer: time to change? World J Gastroenterol 2013; 19: 3052-3061 [PMID: 23716984 DOI: 10.3748/wjg.v19.i20.3052]
2. Rödel P, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenksa-Lange A, Folprecht G, Sauer R. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687 [PMID: 22627104]
3. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgevater J, Rivera F, de Grammont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116 [PMID: 19451431 DOI: 10.1200/JCO.2008.20.6771]
4. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Azzare S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negrui M, Tronconi MC, Luppì G, Silvano G, Corsi DC, Bocchiacino AM, Chiulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780 [PMID: 21606427 DOI: 10.1200/JCO.2010.34.4911]
5. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennecquin C, Etienne PL, Vendrey V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grilloc C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644 [PMID: 20194850 DOI: 10.1200/JCO.2009.25.8376]
6. Roh MS, Colangelo LH, O’Connell MJ, Youthers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124-5130
Hamid A, Shapiro JD, McMurrick P, Bell S, Porter I, Carne P, Haydon AM. Do patients achieving pathologic complete response (pCR) following neoadjuvant treatment for locally advanced rectal cancer (LARC) need adjuvant chemotherapy? 2014 ASCO Annual Meeting. J Clin Oncol 2014;32:5s

P-Reviewer: Higgins PJ, Kanda T, Koukourakis GV, Mura B
S-Editor: Ji FF
L-Editor: AE
E-Editor: Wu HL
